UBS AM’s Neumora Therapeutics NMRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$405 Buy
+679
New +$940 ﹤0.01% 4186
2025
Q1
– Sell
-72,622
Closed -$770K – 2681
2024
Q4
$770K Buy
+72,622
New +$870K ﹤0.01% 2457

Other funds holding NMRA

UBS AM's NMRA Position: Q3 2026 in Review

UBS AM opened a new position in Neumora Therapeutics (NMRA) in Q3 2026: 679 shares worth $405. The stake represents ﹤0.01% of the portfolio and ranks #4186 among its holdings. This is a return to the name: UBS AM previously reported a position in NMRA as recently as Q4 2024.

UBS AM first reported a position in NMRA in Q4 2024 and has held it in 2 quarters since. The position peaked at $770K in Q4 2024. 100 funds tracked by Wall St. Rank hold NMRA as of Q3 2026.

  • UBS AM held 679 shares of Neumora Therapeutics worth $405 as of Q3 2026.
  • Neumora Therapeutics was a new UBS AM position in Q3 2026.
  • Neumora Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q3 2026, its #4186 holding.
  • UBS AM first reported a position in Neumora Therapeutics in Q4 2024 and has held it in 2 quarters since.
  • UBS AM's Neumora Therapeutics position peaked at $770K in Q4 2024.
  • 100 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q3 2026.

Based on UBS AM's 13F filing for Q3 2026, filed 16 Nov 2026.